The prevalence and role of human papillomavirus genotypes in primary cervical screening in the northeast of China

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Wang, Shizhuo ^a   Wei, Heng ^a   Wang, Ning ^a   Zhang, Shulan ^a   Zhang, Yao ^a   Ruan, Qiang ^a   Jiang, Weiguo ^a   Xiao, Qian ^a   Luan, Xiaomei ^a   Qian, Xiuyan ^a   Zhang, Lili ^a   Gao, Xiang ^a   Sun, Xiaowei ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cervical cancer; Cervical screening; Human papillomavirus genotype; Prognosis

Indexed keywords

VIRUS DNA;

ADULT; AGE DETERMINATION; ARTICLE; CANCER PROGNOSIS; CANCER SCREENING; CANCER SURVIVAL; CARCINOGENESIS; CHINA; COLPOSCOPY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PERSISTENT VIRUS INFECTION; POPULATION RESEARCH; PREVALENCE; SQUAMOUS CELL CARCINOMA; SURVIVAL PREDICTION; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERUS CARCINOMA; WART VIRUS;

CERVIX UTERI; CHINA; FEMALE; GENOTYPE; HUMANS; MASS SCREENING; NEOPLASM STAGING; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PREVALENCE; PROGNOSIS; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84864308245     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-160     Document Type: Article

References (22)

1. Cuzick J, Szarewski A, Terry G, et al. Human papillomavirus testing in primary cervical cancer screening. Lancet 1995, 345:1533-1536. 10.1016/S0140-6736(95)91086-7, 7791438.
2. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370:1764-1772. 10.1016/S0140-6736(07)61450-0, 17919718.
3. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomvarus types associated with cervical cancer. New Eng J Med 2003, 348:518-527. 10.1056/NEJMoa021641, 12571259.
4. Devilliers EM. Heterogeneity of the human papillomavirus group. J Virol 1989, 63:4898-4903. 251129, 2552162.
5. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423-428. 10.1056/NEJM199802123380703, 9459645.
6. Moscicki AB, Shibosji S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998, 132:277-284. 10.1016/S0022-3476(98)70445-7, 9506641.
7. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide prospective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87:796-802. 10.1093/jnci/87.11.796, 7791229.
8. Liu X, Zhang S, Ruan Q, Ji Y, Ma L, Zhang Y. Prevalence and type distribution of human papillomavirus in women with cervical lesions in Liaoning Province, China. Int J Gynecol Cancer 2010, 20:147-153. 10.1111/IGC.0b013e3181c20860, 20130516.
9. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88:63Y73.
10. Zhao Y, Lin H, Shen D, et al. Distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China. Pathol Int 2008, 58:643Y647.
11. Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JC, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 2010, 70:8569-8577. 10.1158/0008-5472.CAN-10-0621, 20978200.
12. Wang S, Zhang S. Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin Exp Metastasis 2011, 28(6):581-591. 10.1007/s10585-011-9393-9, 21607803.
13. Waggoner SE. Cervical cancer. Lancet 2003, 361:2217-2225. 10.1016/S0140-6736(03)13778-6, 12842378.
14. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265. 10.1136/jcp.55.4.244, 1769629, 11919208.
15. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human Papillomavirus Testing in the Prevention of Cervical Cancer. J Natl Cancer Inst 2011, 103:368-383. 10.1093/jnci/djq562, 3046952, 21282563.
16. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26(Suppl 10):K29-K41.
17. Lai CH, Chang CJ, Huang HJ, Hsueh S, Chao A, Yang JE, et al. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. J Clin Oncol 2007, 25:3628-3634. 10.1200/JCO.2007.11.2995, 17704412.
18. Lai CH, Chao A, Chang CJ, Huang CC, Wang LC, Hsueh S, et al. Age factor and implication of human papillomavirus type-specific prevalence in women with normal cervical cytology. Epidemiol Infect 2011, 28:1-8. [Epub ahead of print].
19. Burger RA, Monk BJ, Kurosaki T, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996, 88:1361-1368. 10.1093/jnci/88.19.1361, 8827013.
20. Lombard I, Vincent-Salomon A, Validire P, et al. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol 1998, 16:2613-2619.
21. Schwartz SM, Daling JR, Shera KA, et al. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol 2001, 19:1906-1915.
22. Xueqian W, Xiuyun T, Fangfang L, et al. Detection of HPV DNA in esophageal cancer specimens from different regions and ethnic groups: a descriptive study. BMC Cancer 2010, 10:19. 10.1186/1471-2407-10-19, 2826296, 20078887.